On 12 June 2026, Fine Foods Group completed the acquisition of 100% of Sofar S.p.A. from Alfasigma S.p.A., a global pharmaceutical company based in Italy with more than 75 years of history. The transaction, closed for a cash consideration of €23.4 million, coincides with the full operational launch of Fine Foods’ recently expanded pharmaceutical hub in Brembate, near Bergamo in Lombardy, Italy, following an industrial investment of more than €50 million.
Through this dual strategic move, the Italian Contract Solutions Development & Manufacturing Organization (CSDMO), listed on Euronext STAR Milan, is expanding its production capacity and diversifying its technology portfolio to compete more effectively in the global pharmaceutical market.
Strategic manufacturing impact
Sofar’s integration into Fine Foods’ industrial footprint strengthens the Group’s expertise and expands its production capacity in liquid and semi-solid pharmaceutical forms. The agreements maintain production continuity and establish a long-term commercial partnership with Alfasigma, reinforcing the Group’s role as an integrated reference partner for major multinational companies.
At the same time, Fine Foods is advancing internal growth by expanding its state-of-the-art manufacturing site for solid oral pharmaceutical forms. The facility has received official production authorisation from the Italian Medicines Agency (AIFA) and complies with European GMP requirements. With the addition of the new integrated industrial building, covering approximately 10,000 square metres and specialising in tablet production and blister packaging, Fine Foods’ Pharma division now spans 26,100 square metres.
From an engineering standpoint, the new Brembate plant is designed for highly regulated markets. It includes 140 km of data cables, an air-handling capacity of 340,000 m³/h, 716 fire sprinklers and 21,000 LED lamps. The installed machinery is state-of-the-art and highly innovative. Through this addition and the integration of Sofar’s site in Trezzano Rosa, near Milan, the Group has increased its workforce to more than 1,000 employees, giving the international market access to a flexible, diversified production network.
CSDMO positioning and cross-market convergence
Founded in 1984, Fine Foods serves international markets by moving beyond the traditional CDMO model and positioning itself as a solutions provider. Operating exclusively under contract for a loyal international customer base, Fine Foods is a strategic end-to-end partner providing comprehensive support that covers scientific and formulation development using its Research and Development (R&D) laboratories, scale-up, industrial production and final packaging.
The Group operates globally as an “Invisible Expert”, working behind the scenes to strengthen the identity and effectiveness of customer brands through complex, flexible development processes. Strategic diversification across the Pharma, Nutra and Cosmetics business units, and their gradual integration, is a core organisational factor, designed to create commercial synergies and transfer technological knowledge and operational expertise across health and beauty industries.
This cross-sector convergence results into high-value-added industrial solutions, which were recently presented at leading global trade fairs. In March, Fine Cosmetics made its official debut at Cosmoprof Worldwide Bologna, highlighting its solid stick cosmetics and integrated Beauty In&Out solutions.
Most recently, during Vitafoods Europe in Barcelona, the Group strengthened its integrated vision of wellbeing, combining nutraceutical and cosmetic expertise, by presenting new ‘In&Out’ solutions. These include formulations designed to support metabolism in line with GLP-1 trends, alongside a holistic approach to longevity and skin wellbeing, reflecting an integrated interpretation of how contemporary wellbeing is evolving. To complete the range, the Group introduced cutting-edge concepts based on internal efficacy studies of the Biotic3® line.
Responsible governance and development strategy
To ensure the high standing required by global partners, the Group’s development is supported by rigorous governance principles that extend beyond financial performance. As a Benefit Corporation since 2021 and a signatory to the United Nations Global Compact, Fine Foods follows a clear strategy focused on process decarbonisation, energy efficiency and optimised use of production resources.
Its medium- to long-term investment approach balances infrastructure development with financial strength by improving workflow efficiency, advanced process automation, energy transition through on-site renewable energy generation, and operational efficiency across its manufacturing sites. The Group’s focus on human capital, supported by technical and continuous training programmes aligned with its corporate code of ethics and transparency principles, remains central to strengthening its quality-driven growth and resilience in the global pharmaceutical market.
